ImmunityBio Stock Fell After FDA Letter, Derivative Suit Says
By Zak Kostro · April 20, 2026, 8:26 PM EDT
Biotechnology company ImmunityBio Inc.'s stock slipped by 21% after misleading statements on a podcast by the company's founder about its lead cancer drug prompted the issuance of a warning letter from the...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login